Share-based Payment Arrangement, Expense in USD of Autolus Therapeutics plc from 2016 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Autolus Therapeutics plc quarterly/annual Share-based Payment Arrangement, Expense history and change rate from 2016 to Q3 2025.
  • Autolus Therapeutics plc Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $3.84M, a 4.6% decline year-over-year.
  • Autolus Therapeutics plc Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $17.2M, a 37.9% increase year-over-year.
  • Autolus Therapeutics plc annual Share-based Payment Arrangement, Expense for 2024 was $15.5M, a 38.1% increase from 2023.
  • Autolus Therapeutics plc annual Share-based Payment Arrangement, Expense for 2023 was $11.2M, a 6.74% decline from 2022.
  • Autolus Therapeutics plc annual Share-based Payment Arrangement, Expense for 2022 was $12M, a 20.9% increase from 2021.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Autolus Therapeutics plc Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 $17.2M $3.84M -$185K -4.6% 01 Jul 2025 30 Sep 2025 10-Q 12 Nov 2025
Q2 2025 $17.4M $4.29M +$1.36M +46.3% 01 Apr 2025 30 Jun 2025 10-Q 12 Aug 2025
Q1 2025 $16.1M $2.87M +$583K +25.5% 01 Jan 2025 31 Mar 2025 10-Q 08 May 2025
Q4 2024 $15.5M $6.23M +$2.98M +91.4% 01 Oct 2024 31 Dec 2024 10-K 20 Mar 2025
Q3 2024 $12.5M $4.02M +$1.16M +40.4% 01 Jul 2024 30 Sep 2024 10-Q 12 Nov 2025
Q2 2024 $11.3M $2.94M +$267K +10% 01 Apr 2024 30 Jun 2024 10-Q 12 Aug 2025
Q1 2024 $11.1M $2.28M -$132K -5.46% 01 Jan 2024 31 Mar 2024 10-Q 08 May 2025
Q4 2023 $11.2M $3.26M 01 Oct 2023 31 Dec 2023 10-K 20 Mar 2025
Q3 2023 $2.86M -$473K -14.2% 01 Jul 2023 30 Sep 2023 10-Q 12 Nov 2024
Q2 2023 $2.67M 01 Apr 2023 30 Jun 2023 10-Q 08 Aug 2024
Q1 2023 $2.42M 01 Jan 2023 31 Mar 2023 10-Q 17 May 2024
Q3 2022 $3.34M 01 Jul 2022 30 Sep 2022 10-Q 09 Nov 2023
Q1 2021 $13.1M -$670K -$6.91M -111% 01 Jan 2021 31 Mar 2021 6-K 06 May 2021
Q4 2020 $20M $4.24M -$2.21M -34.3% 01 Oct 2020 31 Dec 2020 20-F 07 Mar 2023
Q3 2020 $22.2M $4.25M -$3.46M -44.9% 01 Jul 2020 30 Sep 2020 6-K 05 Nov 2020
Q2 2020 $25.7M $5.31M -$3.56M -40.2% 01 Apr 2020 30 Jun 2020 6-K 06 Aug 2020
Q1 2020 $29.3M $6.24M -$1.13M -15.3% 01 Jan 2020 31 Mar 2020 6-K 06 May 2021
Q4 2019 $30.4M $6.45M +$3.05M +90% 01 Oct 2019 31 Dec 2019 20-F 10 Mar 2022
Q3 2019 $27.3M $7.71M 01 Jul 2019 30 Sep 2019 6-K 05 Nov 2020
Q2 2019 $8.87M +$6.49M +273% 01 Apr 2019 30 Jun 2019 6-K 06 Aug 2020
Q1 2019 $7.37M 01 Jan 2019 31 Mar 2019 6-K 07 May 2020
Q4 2018 $3.39M 01 Oct 2018 31 Dec 2018 20-F 04 Mar 2021
Q2 2018 $2.38M 01 Apr 2018 30 Jun 2018 6-K 08 Aug 2019

Autolus Therapeutics plc Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 $15.5M +$4.27M +38.1% 01 Jan 2024 31 Dec 2024 10-K 20 Mar 2025
2023 $11.2M -$810K -6.74% 01 Jan 2023 31 Dec 2023 10-K 20 Mar 2025
2022 $12M +$2.08M +20.9% 01 Jan 2022 31 Dec 2022 10-K 21 Mar 2024
2021 $9.94M -$10.1M -50.4% 01 Jan 2021 31 Dec 2021 10-K 21 Mar 2024
2020 $20M -$10.4M -34.1% 01 Jan 2020 31 Dec 2020 20-F 07 Mar 2023
2019 $30.4M +$23.6M +349% 01 Jan 2019 31 Dec 2019 20-F 10 Mar 2022
2018 $6.77M +$3.61M +115% 01 Oct 2017 30 Sep 2018 20-F 03 Mar 2020
2017 $3.15M +$896K +39.7% 01 Oct 2016 30 Sep 2017 20-F 03 Mar 2020
2016 $2.26M 01 Oct 2015 30 Sep 2016 20-F 25 Feb 2019
* An asterisk sign (*) next to the value indicates that the value is likely invalid.